Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2096666 Target Snapshot

Glutamate NMDA receptor; Grin1/Grin2b · PROTEIN COMPLEX · Rattus norvegicus

802Compounds
85Assays
4Approved Drugs
532.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P35439. Use UniProt P35439 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P35439 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate NMDA receptor; Grin1/Grin2b as ChEMBL target CHEMBL2096666, mapped to UniProt P35439. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate NMDA receptor; Grin1/Grin2b
PROTEIN COMPLEX · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL2096666
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35439
Glutamate receptor ionotropic, NMDA 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate NMDA receptor; Grin1/Grin2b is the right protein anchor across sources, using UniProt P35439 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate receptor ionotropic, NMDA 1
UniProt AccessionP35439
Component TypeProtein
Sequence Length938 aa

Glutamate receptor ionotropic, NMDA 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Glutamate NMDA receptor; Grin1/Grin2b, mapped to UniProt P35439. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.

Mapped IDP35439
Review nameGlutamate NMDA receptor; Grin1/Grin2b
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

4
Approved
3
Phase III
4
Phase II
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC50381.0
KI50.0
EC50101.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL19849 8.7 IC50 2.0 Preclinical
CHEMBL19506 8.52 IC50 3.0 Preclinical
CHEMBL19419 8.4 IC50 4.0 Preclinical
CHEMBL119778 8.1 IC50 8.0 Preclinical
CHEMBL305195 8.05 IC50 9.0 Preclinical
CHEMBL19404 8.05 IC50 9.0 Preclinical
CHEMBL1203902 7.96 IC50 11.0 Preclinical
CHEMBL174632 7.92 IC50 12.0 Preclinical
CHEMBL19636 7.85 IC50 14.0 Preclinical
CHEMBL283753 7.82 IC50 15.0 Preclinical
Distribution

pChEMBL Value Distribution

86
5.0
53
5.5
60
6.0
57
6.5
36
7.0
24
7.5
6
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GLYCINE
CHEMBL773
Approved 1982
KETAMINE
CHEMBL742
Approved 1970
Assay Landscape

Assay Landscape

85
Total Assays
283
Tested Compounds
3
Assay Types
Binding — 66 assays, 283 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 57 218 5.7
assay format 7 46 5.6
protein complex format 1 0
tissue-based format 1 19 7.5
Functional — 16 assays, 193 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 14 153 5.5
assay format 2 40 5.9
ADME — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine